• Users Online: 206
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 19  |  Issue : 2  |  Page : 140-146

Aflibercept for macular edema after branch retinal vein occlusion


Department of Ophthalmology, Alexandria University, Alexandria, Egypt

Correspondence Address:
Mahmoud Abouhussein
8 Hassan Allam Street Smouha, Alexandria 1103
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/DJO.DJO_84_17

Rights and Permissions

Purpose The aim was to evaluate the real-world results of aflibercept in the treatment of macular edema due to branch retinal vein occlusion (BRVO) without prior treatment. Patients and methods The study included patients with treatment-naive symptomatic BRVO causing macular edema with a best corrected visual acuity (VA) of 0.1 or better, central macular thickness (CMT) of more than 300 μm, and a duration less of than 6 months. Patients received intravitreal 2.0 mg of aflibercept. Follow-up examinations were performed monthly after the first injection for at least 6 months. At each visit, complete examination and optical coherence tomography scans were performed with recording of the best corrected VA and CMT on optical coherence tomography. At the monthly follow-up visits, additional Aflibercept injections were given as needed (pro-re-nata) when intraretinal/subretinal fluid was still present. Results A total of 25 patients were included in the study. Their age ranged from 42 to 75 years with a mean of 61.12±8.34 years. There were 16 men and nine women. Duration of vein occlusion ranged from 10 to 50 days with a mean of 21.8±12.29 days. Baseline logarithm of the minimal angle of resolution VA mean was 0.790±0.16. It improved at the 6-month follow-up visit to 0.244±0.22, which was statistically significant (P=0.001). Baseline CMT mean was 538.84±186.96 µm. It improved at the end of follow-up to 284.680±68.22 µm, which was statistically significant (P=0.001). Conclusion Aflibercept given with pro-re-nata regimen was safe and effective in the treatment of macular edema after BRVO.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed106    
    Printed8    
    Emailed0    
    PDF Downloaded34    
    Comments [Add]    

Recommend this journal